Gilead Sciences (GILD) Q1 2026 (USD): Adj. EPS 2.03 (exp. 1.91), Revenue 6.96bln (exp. 6.91bln), guides FY26 Adj. EPS between -1.05 to -0.65 and product sales between 30-30.4bln (exp. 30bln), outlook reduced due to USD 11.5bln of charges

Gilead Sciences reported a Q1 beat on both adjusted EPS and revenue, indicating better-than-expected momentum in the current quarter. However, the company's guidance for FY26 shows a significant downturn, reflecting substantial charges, which may lead to market concerns about its future profitability and stability. This mixed outcome suggests potential volatility in GILD's stock and could also impact investor sentiment broadly in the biotech sector.